- Home
- ZBRA vs MDGL Comparison
ZBRA vs MDGL Comparison
Compare ZBRA & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ZBRA | MDGL |
|---|---|---|
| Founded | 1969 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.6B | 12.5B |
| IPO Year | 1991 | N/A |
Fundamental Metrics
Financial Performance| Metric | ZBRA | MDGL |
|---|---|---|
| Price | $255.96 | $558.05 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 14 |
| Target Price | $340.57 | ★ $580.77 |
| AVG Volume (30 Days) | ★ 569.8K | 274.1K |
| Earning Date | 02-12-2026 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 34.78 | N/A |
| EPS | ★ 9.93 | N/A |
| Revenue | ★ $5,255,000,000.00 | $740,640,000.00 |
| Revenue This Year | $10.26 | $435.63 |
| Revenue Next Year | $10.00 | $52.56 |
| P/E Ratio | $25.45 | ★ N/A |
| Revenue Growth | 12.87 | ★ 864.21 |
| 52 Week Low | $205.73 | $265.00 |
| 52 Week High | $427.76 | $615.00 |
Technical Indicators
Market Signals| Indicator | ZBRA | MDGL |
|---|---|---|
| Relative Strength Index (RSI) | 54.13 | 46.15 |
| Support Level | $242.64 | $578.00 |
| Resistance Level | $247.25 | $598.79 |
| Average True Range (ATR) | 6.25 | 19.97 |
| MACD | 0.52 | -3.94 |
| Stochastic Oscillator | 61.89 | 32.59 |
Price Performance
Historical ComparisonAbout ZBRA Zebra Technologies Corporation
Zebra Technologies is a leading provider of automatic identification and data capture technology to enterprises. Its solutions include barcode printers and scanners, mobile computers, and workflow optimization software. The firm primarily serves the retail, transportation logistics, manufacturing, and healthcare markets, designing custom solutions to improve efficiency at its customers.
About MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.